Cargando…

Multi-Objective Drug Design Based on Graph-Fragment Molecular Representation and Deep Evolutionary Learning

Drug discovery is a challenging process with a huge molecular space to be explored and numerous pharmacological properties to be appropriately considered. Among various drug design protocols, fragment-based drug design is an effective way of constraining the search space and better utilizing biologi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukaidaisi, Muhetaer, Vu, Andrew, Grantham, Karl, Tchagang, Alain, Li, Yifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291509/
https://www.ncbi.nlm.nih.gov/pubmed/35860028
http://dx.doi.org/10.3389/fphar.2022.920747
_version_ 1784749151663161344
author Mukaidaisi, Muhetaer
Vu, Andrew
Grantham, Karl
Tchagang, Alain
Li, Yifeng
author_facet Mukaidaisi, Muhetaer
Vu, Andrew
Grantham, Karl
Tchagang, Alain
Li, Yifeng
author_sort Mukaidaisi, Muhetaer
collection PubMed
description Drug discovery is a challenging process with a huge molecular space to be explored and numerous pharmacological properties to be appropriately considered. Among various drug design protocols, fragment-based drug design is an effective way of constraining the search space and better utilizing biologically active compounds. Motivated by fragment-based drug search for a given protein target and the emergence of artificial intelligence (AI) approaches in this field, this work advances the field of in silico drug design by (1) integrating a graph fragmentation-based deep generative model with a deep evolutionary learning process for large-scale multi-objective molecular optimization, and (2) applying protein-ligand binding affinity scores together with other desired physicochemical properties as objectives. Our experiments show that the proposed method can generate novel molecules with improved property values and binding affinities.
format Online
Article
Text
id pubmed-9291509
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92915092022-07-19 Multi-Objective Drug Design Based on Graph-Fragment Molecular Representation and Deep Evolutionary Learning Mukaidaisi, Muhetaer Vu, Andrew Grantham, Karl Tchagang, Alain Li, Yifeng Front Pharmacol Pharmacology Drug discovery is a challenging process with a huge molecular space to be explored and numerous pharmacological properties to be appropriately considered. Among various drug design protocols, fragment-based drug design is an effective way of constraining the search space and better utilizing biologically active compounds. Motivated by fragment-based drug search for a given protein target and the emergence of artificial intelligence (AI) approaches in this field, this work advances the field of in silico drug design by (1) integrating a graph fragmentation-based deep generative model with a deep evolutionary learning process for large-scale multi-objective molecular optimization, and (2) applying protein-ligand binding affinity scores together with other desired physicochemical properties as objectives. Our experiments show that the proposed method can generate novel molecules with improved property values and binding affinities. Frontiers Media S.A. 2022-07-04 /pmc/articles/PMC9291509/ /pubmed/35860028 http://dx.doi.org/10.3389/fphar.2022.920747 Text en Copyright © 2022 Her Majesty the Queen in Right of Canada. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Mukaidaisi, Muhetaer
Vu, Andrew
Grantham, Karl
Tchagang, Alain
Li, Yifeng
Multi-Objective Drug Design Based on Graph-Fragment Molecular Representation and Deep Evolutionary Learning
title Multi-Objective Drug Design Based on Graph-Fragment Molecular Representation and Deep Evolutionary Learning
title_full Multi-Objective Drug Design Based on Graph-Fragment Molecular Representation and Deep Evolutionary Learning
title_fullStr Multi-Objective Drug Design Based on Graph-Fragment Molecular Representation and Deep Evolutionary Learning
title_full_unstemmed Multi-Objective Drug Design Based on Graph-Fragment Molecular Representation and Deep Evolutionary Learning
title_short Multi-Objective Drug Design Based on Graph-Fragment Molecular Representation and Deep Evolutionary Learning
title_sort multi-objective drug design based on graph-fragment molecular representation and deep evolutionary learning
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291509/
https://www.ncbi.nlm.nih.gov/pubmed/35860028
http://dx.doi.org/10.3389/fphar.2022.920747
work_keys_str_mv AT mukaidaisimuhetaer multiobjectivedrugdesignbasedongraphfragmentmolecularrepresentationanddeepevolutionarylearning
AT vuandrew multiobjectivedrugdesignbasedongraphfragmentmolecularrepresentationanddeepevolutionarylearning
AT granthamkarl multiobjectivedrugdesignbasedongraphfragmentmolecularrepresentationanddeepevolutionarylearning
AT tchagangalain multiobjectivedrugdesignbasedongraphfragmentmolecularrepresentationanddeepevolutionarylearning
AT liyifeng multiobjectivedrugdesignbasedongraphfragmentmolecularrepresentationanddeepevolutionarylearning